/, Medication, Research/New data on ADHD study drug NS2359

New data on ADHD study drug NS2359

NS2359 is a mixed monoamine reuptake inhibitor.  A study looked at the efficacy of NS2359 versus placebo in a double-blind randomized trial.

There was no statistical difference in the total ADHD-RS scale score between those taking NS2359 and placebo.  However, when looking at the inattentive type of ADHD, 41% of those who took NS2359 had an improvement, compared with 7% of the control group. 


Wilens, et al. (2008). A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD.  Behavioral and Brain Functions 4(24).


By |2016-10-05T06:46:13+00:00June 25th, 2008|Categories: ADHD, Medication, Research|Tags: , , , , , , , |Comments Off on New data on ADHD study drug NS2359

About the Author:

Dr. Stephanie Sarkis is a National Certified Counselor (NCC), Licensed Mental Health Counselor (LMHC), and AMHCA Diplomate and Clinical Specialist in Child and Adolescent Counseling based in Tampa Bay, Florida, where she specializes in the treatment of ADD/ADHD. Dr. Sarkis conducts evaluations, testing, diagnosis, and counseling services. She also is a public speaker, consultant, coach, and is a facilitator in collaborative law.